Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.

about

Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.

Item

http://www.wikidata.org/entity/Q50673073

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Prognostic impact of normaliza ...... rcinoma with arterial contact.

@en

Prognostic impact of normaliza ...... rcinoma with arterial contact.

@nl

type

Item

label

Prognostic impact of normaliza ...... rcinoma with arterial contact.

@en

Prognostic impact of normaliza ...... rcinoma with arterial contact.

@nl

prefLabel

Prognostic impact of normaliza ...... rcinoma with arterial contact.

@en

Prognostic impact of normaliza ...... rcinoma with arterial contact.

@nl

P1476

Prognostic impact of normaliza ...... rcinoma with arterial contact.

@en

P2093

Kenichiro Uemura

http://www.w3.org/2001/XMLSchema#string

Kenjiro Okada

http://www.w3.org/2001/XMLSchema#string

Naoya Nakagawa

http://www.w3.org/2001/XMLSchema#string

Naru Kondo

http://www.w3.org/2001/XMLSchema#string

Shinya Takahashi

http://www.w3.org/2001/XMLSchema#string

Taijiro Sueda

http://www.w3.org/2001/XMLSchema#string

Takeshi Sudo

http://www.w3.org/2001/XMLSchema#string

Yasushi Hashimoto

http://www.w3.org/2001/XMLSchema#string

Yoshiaki Murakami

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.

Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer

Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.

Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.

P2888

s00280-017-3281-1

P304

801-811

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-017-3281-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28314992

http://www.w3.org/2001/XMLSchema#string